

BMJ Open Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review

Francisco Gómez-García,^{1,2} Pedro Jesús Gómez-Arias,^{1,2} Jorge Hernandez,³ Ana María Montilla,^{2,4} Jesús Gay-Mimbrera,² Macarena Aguilar-Luque,² Isabel Viguera-Guerra,^{2,5} Antonio Velez García-Nieto,^{1,2} Beatriz Isla-Tejera,^{2,3} Juan Ruano^{1,2}

To cite: Gómez-García F, Gómez-Arias PJ, Hernandez J, *et al*. Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review. *BMJ Open* 2019;9:e028303. doi:10.1136/bmjopen-2018-028303

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2018-028303>).

FG-G and JR contributed equally.

Received 3 December 2018

Revised 12 April 2019

Accepted 15 April 2019



© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Juan Ruano;
juanruanoruiz@mac.com

ABSTRACT

Introduction The Janus kinase and Signal Transducer and Activator of Transcription protein (JAK/STAT) pathway is known to be involved in inflammatory and neoplastic skin diseases, like psoriasis, atopic dermatitis, alopecia areata, vitiligo and melanoma. Improved knowledge of the components of this pathway has allowed the development of drugs, which act by inhibiting the pathway, blocking specific components. This offers new therapeutic opportunities. Although evidence on the use of JAK/STAT blockades in dermatological diseases is growing, none have been approved for use in treating skin diseases. The aim of this study is to develop an a priori protocol to broadly review the available evidence on the use of drugs targeting the JAK/STAT pathway in the treatment of dermatological diseases.

Methods and analysis For the conduction of the scoping review protocol, we will employ an established scoping review methodology described in the Joanna Briggs Institute manual. This methodology outlines a five-stage approach: (1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data and (5) collate, summarise and report the results, with an optional consultation exercise. Finally, we will use the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews to present the results.

Ethics and dissemination Since this is a review of the literature, ethics approval is not indicated. We will disseminate the findings from this study in publications in peer-reviewed journals as well as presentations at relevant national and international conferences.

INTRODUCTION

Improving knowledge of the molecular biology of the cell, and its adaptation to the disease pathogenesis, have allowed the design of new drugs directed against key targets in signalling pathway regulation. In this sense, the Janus kinases (JAKs) and Signal Transducer and Activator of Transcription (STATs) proteins (JAK/STAT) pathway is one of a

Strengths and limitations of this study

- Strengths of this study include the importance of unrevealing uncertainty about evidence of using drugs targeting Janus kinase and Signal Transducer and Activator of Transcription proteins pathway when prescribed as *off-label* for dermatological diseases in the clinical setting.
- We will use an established scoping review methodology, a systematic search developed by two health sciences librarians and systematic screening and data abstraction carried out in duplicate.
- A limitation of this review is the potential to miss relevant articles, especially in the grey literature. To mitigate this, we will screen meeting abstracts to identify any missed articles describing case reports not published in journals and scan reference lists of included articles and similar reviews.

handful of pleiotropic routes used to transduce multiple extracellular signals involved in cell proliferation, differentiation, migration and apoptosis.¹ Alterations in the regulation of this process have been associated with pathological events fundamentally related to immunomodulatory and neoplastic (mainly haematological) disorders. In addition, they have been related to the pathophysiology of several dermatological diseases. Therefore, drugs that act on the JAK/STAT pathway represent an opportunity for the treatment of these disorders.²

The JAK family is comprised by four types of cytoplasmic tyrosine kinases: JAK1, JAK2, JAK3 and Tyk2.³ STAT, of which there are seven different subtypes (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6), is the other fundamental component of the cascade.⁴ After being phosphorylated by JAK, STAT translocates to the nucleus to induce

the transcription of specific genes. Different types of ligands, from cytokines, such as interleukins (ILs), to hormones, such as erythropoietin, activate this pathway to produce changes in the cell, and eventually in tissue physiology. Some of these molecules have been shown to be important, directly or indirectly, in the development of dermatological diseases. Examples of these are IL-2 and its family, IL-23, interferon alpha⁵ and IL-17.⁶ The overall pathway has shown its implication in the pathophysiology of diseases such as psoriasis, atopic dermatitis, lupus erythematosus, melanoma or pyoderma gangrenosum.⁷

This knowledge has led to the development of drugs that act on the JAK component of the pathway, by selectively inhibiting one (filgotinib, JAK1; pacritinib, JAK2; decernotinib, JAK3) or more than one (tofacitinib, JAK1 and JAK3; ruxolitinib, baricitinib, JAK1 and JAK2) JAK protein.⁸ Ruxolitinib and tofacitinib were the first drugs of this class to be approved by the FDA—in 2011 for myelofibrosis and in 2012 for rheumatoid arthritis, respectively.^{9 10}

So far, no JAK/STAT inhibitors have been approved a license for the treatment of dermatological diseases. However, evidence exists resulting from the off-label use of these drugs, specifically tofacitinib and ruxolitinib, in different skin diseases. Knowing the efficacy and safety profile of each drug used in different dermatological diseases is essential to establish their risk–benefit balance.

Improving knowledge requires ordering evidence, establishing gaps in the evidence and formulating questions that can be answered using systematic synthesis and analysis techniques. The aim of this is to develop guidelines that give support to physicians in making effective decisions in clinical practice. For this purpose, secondary scientific studies can develop methodologies that adapt to the specific needs of the formulated problem. The application of JAK inhibitors for the treatment of dermatological disorders is still in its early stages, and we consider it necessary to broadly review the knowledge available to date. Otherwise, the conduction of studies aimed at answering specific questions can lead to synthesis efforts that cannot be quantified.¹¹

A scope review is a form of scientific synthesis that addresses an exploratory research question, with the aim of mapping key concepts and gaps in research related to a defined area or field.¹² The aim of this protocol is to define the methodology that will be used to broadly synthesise the available evidence on the use of inhibitors of the JAK/STAT pathway in dermatological diseases.

METHODS

Protocol design

The aim of the study is to broadly address the published evidence on drugs targeting JAK proteins in the treatment dermatological diseases, for three purposes: (a) to structure the existing knowledge in this field; (b) to establish areas where there may be gaps in the evidence; (c) to formulate new questions that can be answered following

the methodology of systematic reviews. With this intention, we will use the methodology recently described to conduct scoping reviews.¹³ This methodology outlines a five-stage approach (table 1): (1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data and (5) collate summarise and report the results, with an optional consultation exercise. Finally, we will use the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews to present the results.¹⁴ This protocol is reported following the recommendations of the PRISMA for protocols statement. A checklist for this review protocol has been provided in a Supplementary file 1.

Inclusion criteria

We will use participants, concept, context (PCC) mnemonic rule to define the inclusion criteria as follows:

Participants

All studies that include evidence on the use of JAK protein inhibitors in humans will be included. No restrictions regarding age, ethnicity, study design or any other characteristics will be made.

Concept

We will review the existing literature on drugs targeting JAK proteins in the treatment of dermatological diseases: indications, epidemiology, genetics, efficacy and safety.

Context

We will not limit the context to a particular setting or country.

Research question

What are the indications, epidemiology, genetics, efficacy and safety of drugs targeting proteins of STAT/JAK pathway for the treatment of dermatological diseases?

Identifying relevant literature

A systematic search developed by two health sciences librarians will perform using a three-step literature search. The first step will include an initial limited search of the MEDLINE and EMBASE databases (table 2). Then, we will carry out analyses of: the text contained in the titles, abstracts of retrieved papers and the index terms used to describe the articles. In second step, we will search the same databases using the identified keywords and index terms. Additionally, CINAHL, Scopus and Web of Science to the search engines will be searched in this second step. Third, the reference list of all identified reports and articles will be searched for additional studies. We will contact authors of primary studies or reviews for further information, if relevant. We have established a time frame of 4 weeks after sending authors a mail requesting information about their study or publication. We will include all studies published in English until October 2018. The process of searching, extracting key words and filtering and excluding studies, will be carried out independently and by duplicate by at least two researchers and in case of

Table 1 Stages of the scoping reviews

1. Research question identified	1.1. Overarching goal	To explore the depth and breadth of evidence for the indications, epidemiology, genetics, efficacy and safety of drugs that act on JAK/STAT pathway in the treatment of patients with dermatological diseases.
	1.2. Research question	What are the indications, epidemiology, genetics, efficacy and safety of drugs that act on JAK/STAT pathway in the treatment of dermatological diseases?
	1.3. Purposes of this scoping review	<p>1.3.1. Review the evidence of indications for drugs that act on JAK/STAT pathway in the treatment of dermatological diseases.</p> <p>1.3.2. Review the evidence of epidemiology of drugs acting on JAK/STAT pathway in the treatment of dermatological diseases.</p> <p>1.3.3. Review the evidence of genetics of drugs acting on JAK/STAT pathway in the treatment of dermatological diseases.</p> <p>1.3.4. Review the evidence on efficacy of the drugs that act on JAK/STAT pathway in the treatment of dermatological diseases.</p> <p>1.3.5. Review the evidence on safety of drugs that act on JAK/STAT pathway in the treatment of dermatological diseases.</p> <p>1.3.6. Obtain concrete research questions that can be answered through a systematic review.</p> <p>1.3.7. Identify research gaps in the existing literature.</p>
2. Identifying relevant literature	2.1. We will perform a three-step search	<p>2.1.1. First search: an initial limited search of the MEDLINE and EMBASE databases to find keywords in the title, abstract and the index terms used to describe the articles.</p> <p>2.1.2. Second search: a search of MEDLINE and EMBASE using all identified keywords. <i>Additionally, CINAHL, Scopus and Web of Science to the search engines will be searched in this second step.</i></p> <p>2.1.3. Third search: the reference lists of all identified reports and articles will be searched for additional studies.</p>
	2.2. We will include the studies published in full text in English until October 2018.	
	2.3. We will contact authors, of primary studies or reviews, for further information, if this is relevant.	
	2.4. The search and selection will be done by at least two reviewers and in case of disagreement will be decided by agreement with a third reviewer.	
3. Selecting studies	3.1. Inclusion criteria	3.1.1. We will include in the review the studies on the human use of drugs inhibitors of JAK/STAT pathway published on the topics: indications, epidemiology, genetics, efficacy and safety.

Continued

Table 1 Continued

	<p>3.1.2. Design of the studies: we will include guidelines, systematic reviews, randomised clinical trials, observational studies, cross sectional case report and series.</p> <p>3.2.1. We will exclude narrative reviews and studies performed in vitro or using animal models.</p>
3.2. Exclusion criteria	
4. Charting the data	<p>4.1. We will extract the data in a predefined form.</p> <p>4.2. From each study we will extract title, objective, main variables related to patients, intervention, comparator, outcomes (efficacy and safety) and bibliographic data.</p> <p>4.3. We will classify the studies by treatment indication.</p> <p>4.4. The list of studies, variables and data of there view will be published in an online file.</p> <p>4.5. The data collection will be done by at least two reviewers and in case of disagreement will be decided by agreement with a third reviewer.</p>
5. Collating, summarising and reporting results	<p>5.1. The results of comprehensive search will be presented using the PRISMA flow diagram.</p> <p>5.2. We will synthesise qualitatively the evidence obtained ordering it by topics: indications, mechanism of action, efficacy and safety of drugs that act on JAK/STAT pathway to treat dermatological diseases and we will present it in a diagrammatic tabular form and in a descriptive format.</p> <p>5.3. We will use the extension of PRISMA for scoping review for the notification of the review.</p>
6. Differences between the protocol and the overview	<p>Any changes in in the methodology that need to be carried out throughout the study will be detailed together with the results publication.</p>

JAK/STAT, Janus kinase and Signal Transducer and Activator of Transcription protein; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Table 2 Draft of first step of search strategy to be used for at least two electronic databases.

search	
#1	(('tofacitinib' OR 'baricitinib' OR 'ruxolitinib' OR 'ocloacitinib' OR 'upadacitinib' OR 'delgocitinib' OR 'itacitinib' OR 'mometinib' OR peficitinib OR 'decernotinib' OR 'fedratinib' OR 'pacritinib' OR 'filgotinib' OR 'gandotinib' OR 'solcitinib' OR 'lestaurtinib' OR 'janus kinase inhibitor')
#2	(('psoriasis'/exp OR psoriasis) OR 'atopic dermatitis' OR 'alopecia' OR 'contact dermatitis' OR 'vitiligo' OR 'graft versus host reaction' OR 'lichen planus' OR 'pyoderma gangrenosum' OR 'pruritus' OR (eosinophilic AND annulare AND erythema) OR 'male type alopecia' OR 'proteasome associated autoinflammatory syndrome' OR 'sting associated vasculopathy with onset in infancy' OR 'chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome' OR 'hand dermatitis' OR 'discoid lupus erythematosus' OR 'mucocutaneous candidiasis' OR (urticaria AND chronic) OR 'suppurative hidradenitis' OR 'melanoma' OR 'non melanoma skin cancer' OR 'acne' OR 'lichen sclerosus et atrophicus' OR 'pityriasis rubra pilaris' OR 'pemphigus' OR 'skin disease' OR 'rosacea' OR 'scleroderma' OR 'cinca syndrome' OR 'hyperhidrosis' OR 'erythropoietic protoporphyria' OR 'anca associated vasculitis' OR 'seborrheic dermatitis' OR 'herpes simplex' OR 'sjogren syndrome'))
#3	#1 AND #2

disagreement will be decided by agreement with a third reviewer.

Identifying relevant studies

We will apply the inclusion criteria, described previously, for the selection of studies. The process will be carried out by at least two researchers and in case of disagreement will be decided by agreement with a third reviewer.

Charting the data

We will develop a draft charting to record the information that will be relevant to the review.

Questions focusing on:

1. *Mapping studies*: author(s), year of publication, origin/country of origin (where the study was published or conducted), authors affiliation, type of study, a priori design, registration, conflict of interest, funding;
2. *Epidemiological and genetics aspects*: study population and sample size, genetic studies;
3. *Evaluation of the efficacy and safety of drugs for each disease*: intervention type, comparator and details of these, duration of the intervention, dosage, outcomes and details of these and adverse events.

The data collection will be done by at least two reviewers using a piloting customised Google AppSheet form (<https://www.appsheet.com/>) and in case of disagreement will be decided by agreement with a third reviewer. We anticipate that we can start retrieving data in April 2019 and finalising by September 2019.

Collating, summarising and reporting results

The elements of the PCC inclusion criteria will guide the presentation of the data. First, we will present the results of the search in the PRISMA flow chart. Second, we will organise the extracted data for topics defined as follows: indications, mechanism of action, efficacy safety and cost. For each category, a clear explanation will be provided. The results of the scoping review will be presented as a map, in both diagrammatic and tabular form, and in a descriptive format. A narrative summary will accompany

the tabulated and/or charted results and will describe how the results relate to the review objective and question(s).

Differences between the protocol and the overview

Changes in the methodology that need to be carried out throughout the study will be detailed in the results section.

Ethics and dissemination

This study will analyse only anonymised public data of previously conducted studies, and will not involve any new human or animal studies performed by the authors. We will prepare the publication in accordance with PRISMA guideline and its adaptation for scoping reviews. We will publish our findings in peer-reviewed journals and also may present them at conferences.

Patient and public involvement

Patients and or public were not involved in the development of this protocol. The study group developed this study protocol without patient involvement.

CONCLUSION

Here, we have presented a protocol for systematically conducting a scoping review to broadly analyse the available evidence on the indications for and the mechanisms of action, efficacy and safety of JAK/STAT pathway-targeting drugs in the use of dermatological therapy. Evidence-based medicine is intended to optimise decision making by emphasising the use of evidence derived from well-designed and well-conducted research. Currently, most reviews of treatments blocking the JAK/STAT pathway are narrative reviews, which lack the necessary methodological detail to promote reproducibility and reduce the risk of bias.^{15 16} Secondary research methodologies are constantly being developed and must be adapted to the type of research question being asked and the urgency with which the question must be answered.¹⁷

Although we will try to analyse the quality of evidence per variable and disease using Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, probably most of the studies have produced documents communicating partial results following an observational design, which is associated with low or very low quality of evidence. However, we believe that the scoping review methodology is the one of the best suited protocols to answer the question posed in this study. The results will provide unique insights into the available evidence on the use of JAK/STAT pathway-targeting drugs in the treatment of dermatological diseases, facilitating the detection of knowledge gaps and the identification of new questions to address via additional systematic reviews.

Author affiliations

¹Department of Dermatology, Hospital Universitario Reina Sofia, Cordoba, Spain

²Immune-mediated Inflammatory Skin Diseases group, Instituto Maimonides de Investigación Biomedica de Cordoba (IMBIC)/Hospital Universitario Reina Sofia/Universidad de Cordoba, Cordoba, Spain

³Department of Pharmacy, Hospital Universitario Reina Sofia, Cordoba, Spain

⁴University of Cordoba, School of Medicine, Cordoba, Spain

⁵Agencia de Evaluación de Tecnologías Sanitarias (AETSA), Consejería de Salud, Junta de Andalucía, Sevilla, Spain

Acknowledgements The authors are also grateful to the reviewers for their helpful comments and suggestions. We would also like to thank Editage (www.editage.com) for performing English-language editing of this review.

Contributors FG-G and JR conceived the study. FG-G, PJG-A, JH, AMM, JG-M, MA-L, IV-G, AVG-N, BI-T, and JR contributed to the protocol design and plan. FG-G, PJG-A, and JH developed the literature search strategy. All the authors worked collaboratively to draft and revise the manuscript, and read and approved the final version. All the authors made substantive intellectual contributions to the development of this protocol. JR is the guarantor of the review.

Funding This work was supported, in part, by project ICI1400136 (which provided funding for JR), integrated into the National Plan of R+D+I 2008-2011, co-financed by the ISCIII-Subdirección General de Evaluación and European Regional Development Fund (ERDF), by project PIN-0316-2017- Consejería de Salud-Junta de Andalucía (JR). No funding was obtained from any pharmaceutical company. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the funders.

Competing interests None declared.

Ethics approval This protocol relates to a search for previously conducted studies, and does not involve any new human or animal subjects performed by the authors.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

REFERENCES

1. Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. *J Cell Sci* 2004;117:1281–3.
2. Samadi A, Ahmad Nasrollahi S, Hashemi A, *et al*. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature. *J Dermatolog Treat* 2017;28:476–83.
3. Seavey MM, Dobrzanski P. The many faces of Janus kinase. *Biochem Pharmacol* 2012;83:1136–45.
4. Schwartz DM, Bonelli M, Gadina M, *et al*. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. *Nat Rev Rheumatol* 2016;12:25–36.
5. Damsky W, King BA. JAK inhibitors in dermatology: The promise of a new drug class. *J Am Acad Dermatol* 2017;76:736–44.
6. Ghoreschi K, Jesson MI, Li X, *et al*. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). *J Immunol* 2011;186:4234–43.
7. Palanivel JA, Macbeth AE, Chetty NC, *et al*. An insight into JAK-STAT signalling in dermatology. *Clin Exp Dermatol* 2014;39:513–8.
8. Welsch K, Holstein J, Laurence A, *et al*. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. *Eur J Immunol* 2017;47:1096–107.
9. INCYTE. FDA Approves Incyte's Jakafi(TM) (ruxolitinib) for Patients with Myelofibrosis. <https://investor.incyte.com/news-releases/news-release-details/fda-approves-incytes-jakafitm-ruxolitinib-patients-myelofibrosis>.
10. Traynor K. FDA approves tofacitinib for rheumatoid arthritis. *Am J Health Syst Pharm* 2012;69:2120.
11. Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: A systematic review. *J Am Acad Dermatol* 2017;76:e19:745–53.
12. Colquhoun HL, Levac D, O'Brien KK, *et al*. Scoping reviews: time for clarity in definition, methods, and reporting. *J Clin Epidemiol* 2014;67:1291–4.
13. The Joanna Briggs Institute. The Joanna Briggs Institute reviewer's manual. 2015 http://joannabriggs.org/assets/docs/sumari/Reviewers-Manual_Methodology-for-JBI-Scoping-Reviews_2015_v2.pdf (Sept 29 2016).
14. Tricco AC, Lillie E, Zarin W, *et al*. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and explanation. *Ann Intern Med* 2018;169:467–73.
15. Yamaoka K, Saharinen P, Pesu M, *et al*. Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). *Genome Biol* 2004;5:253.
16. O'Shea JJ, Schwartz DM, Villarino AV, *et al*. The JAK-STAT pathway: impact on human disease and therapeutic intervention. *Annu Rev Med* 2015;66:311–28.
17. Moher D, Stewart L, Shekelle P. All in the family: systematic reviews, rapid reviews, scoping reviews, realist reviews, and more. *Syst Rev* 2015;4:183.